Table 1

Estimated IC50 doses of breast cell lines treated with EGFR, MEK, and PI3K inhibitors

Cell Line

Gefitinib (μM)

Cetuximab (μg/mL)

U0126 (uM)

LY294002 (uM)


ME16C

0.3 (0.02)

>100a

19.7 (0.66)

21.2 (0.63)

HME-CC

0.2 (0.01)

>100a

12.7 (0.33)

7.3 (0.17)

SUM102

0.1 (0.002)

2.3 (0.15)

4.3 (0.20)

3.4 (0.10)

SUM149

4.7 (0.14)

>100a

21.8 (0.80)

18.4 (0.48)

MCF-7

21.1 (0.29)

>100a

17.0 (1.15)

3.9 (0.13)

ZR-75-1

11.1 (0.12)

>100a

25.0 (0.74)

2.4 (0.05)


72 h IC50 doses were calculated for the EGFR inhibitors gefitinib, cetuximab, the MEK1/2 inhibitor U0126, and the PI3K inhibitor LY294002.

Note that the standard errors are presented within ()

aNo achievable IC50 dose with doses up to 100 μg/mL

Hoadley et al. BMC Genomics 2007 8:258   doi:10.1186/1471-2164-8-258

Open Data